Animal study · Supplements / medicine · 9 Sept 2026
Ozempic and Wegovy linked to nearly 40% fewer asthma attacks
Source: ScienceDaily
What the research found
Study (observational, real-world records). Imperial College London’s Chloe Bloom and Bohee Lee, presented at the European Respiratory Society Congress, compared UK electronic records of about 20,000–22,000 people starting a GLP-1 medicine versus a sulfonylurea. Semaglutide use was associated with nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups. This is not a trial of GLP-1 drugs as asthma therapy and not a reason to start, stop, or replace a prescribed medicine. Off-label longevity use is clinician-only. Not medical advice.
Evidence level: Animal study. Results in animals or cells often don't carry over to people.
Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34